Obsessive–compulsive disorder

Telstone IOP's Behavioral Health Facility in West Palm Beach, Florida Is Now Open

Retrieved on: 
Friday, July 1, 2022
Department, Patient, Addiction medicine, Wisconsin Department of Children and Families, Eye movement desensitization and reprocessing, Goal, PALM, ERP, OCD, Obsessive–compulsive disorder, IOP, EMDR, Response, DCF, AHCA, Hospital, Pharmaceutical industry, Medicine, Anxiety

WEST PALM BEACH, Fla., July 1, 2022 /PRNewswire/ --Telstone IOP, a behavioral health treatment center in West Palm Beach, Florida, has officially opened its doors and is now accepting admissions for patients in need of treatment for addiction and mental illness.

Key Points: 
  • WEST PALM BEACH, Fla., July 1, 2022 /PRNewswire/ --Telstone IOP, a behavioral health treatment center in West Palm Beach, Florida, has officially opened its doors and is now accepting admissions for patients in need of treatment for addiction and mental illness.
  • At our facility, we provide comprehensive treatment plans and trauma-informed care for any individual who may be suffering from substance use or mental health disorders.
  • Telstone's behavioral health treatment programs are licensed by The Agency For Health Care Administration (AHCA), and the Department of Children and Families (DCF), designed to suit a variety of needs with a patient-centered mindset.
  • Contact our admissions staff today, or visit www.telstoneiop.com , to find out more about the addiction treatment programs, and behavioral health services we offer.

BrainsWay Announces Positive OCD Coverage Policy from Blue Cross Blue Shield® (BCBS) Licensee Highmark BCBS for Deep TMS™

Retrieved on: 
Tuesday, June 21, 2022
Association, Review, FDA, Psychiatry, World, Obsessive–compulsive disorder, Technology, WHO, Deep, Brainsway, Transcranial magnetic stimulation, Compulsions, Company, Knowledge, Insurance, U.S. Securities and Exchange Commission, Research, TASE, Private Securities Litigation Reform Act, Lists of diseases, OCD, Income, Addiction, Tic disorder, Policy, Health, Failure, Obsessions, Quality of life, News, NASDAQ, World Health Organization, Health Care Service Corporation, TMS, Legislation, Patient, Awareness, Highmark, GLOBE, BCBS, Health insurance, Pharmaceutical industry, Medicare

and JERUSALEM, June 21, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Highmark Blue Cross Blue Shield (BCBS) has issued a positive coverage policy applicable to the BrainsWay Deep TMS system for the treatment of obsessive-compulsive disorder (OCD), effective May 2, 2022.

Key Points: 
  • and JERUSALEM, June 21, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Highmark Blue Cross Blue Shield (BCBS) has issued a positive coverage policy applicable to the BrainsWay Deep TMS system for the treatment of obsessive-compulsive disorder (OCD), effective May 2, 2022.
  • A positive coverage policy applicable to Deep TMS was previously issued by Health Care Service Corporation, another large independent licensee of the BCBS Association, which covers approximately 17 million members across five states.
  • We are excited to receive this additional BCBS coverage policy for OCD from Highmark BCBS, one of the largest BCBS health plans in the U.S., said Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay.
  • This positive policy brings the total number of lives eligible for Deep TMS OCD coverage to nearly 70 million, a critical reimbursement achievement for our company.

Industry's Largest Peer-Reviewed Longitudinal Study on Behavioral Telehealth Reveals Levels of Treatment Effectiveness, Duration, and Cost Compared to Traditional Treatment

Retrieved on: 
Tuesday, June 7, 2022
Managed Care, Software, Research, Other Health, Mobile, Wireless, Professional Services, Mental Health, Technology, Science, Insurance, Alternative Medicine, Practice Management, Health, Online, Goal, Journal, Mental health, Journal of Medical Internet Research, OCD, Response, Obsessive–compulsive disorder, Awareness, Medicine, Patient, Tic disorder, Research, Quality of life, Diagnosis, Industry, ERP, Health insurance

The response rates and symptom reductions were comparable regardless of whether the patient presented with mild, moderate, or severe symptoms.

Key Points: 
  • The response rates and symptom reductions were comparable regardless of whether the patient presented with mild, moderate, or severe symptoms.
  • For an industry focused on transitioning to value-based care, these results represent equivalent quality outcomes at substantial cost savings over traditional ERP treatment, through an enhanced patient experience, said Stephen Smith, chief executive officer of NOCD.
  • NOCD ( https://www.nocd.com ) is the #1 telehealth provider for the treatment of obsessive-compulsive disorder (OCD).
  • Working together with our therapists, patients, health plans, providers, and employers, we are improving the lives of people with OCD.

Addressing America’s Childhood Mental Health Crisis, Elemy Centralizes Diagnostics, Therapy, and Medication to Decrease Time-to-Care

Retrieved on: 
Tuesday, June 7, 2022
Mental Health, Health, Consumer, Technology, Children, Software, Internet, Social anxiety, PTSD, Insurance, Bipolar, Anxiety, Mental health, Doctor of Philosophy, OCD, Lists of diseases, Founders Fund, Depression, ADHD, Panic disorder, Oppositional defiant disorder, Bipolar disorder, Obsessive–compulsive disorder, Topical steroid withdrawal, SoftBank Group, ODD, Hospital Insurance and Diagnostic Services Act, Medication, Diagnosis, Attention deficit hyperactivity disorder, Health, Parent, Autism, Population, General Catalyst, Medicaid, Mixed anxiety–depressive disorder, Post-traumatic stress disorder, Pharmaceutical industry, Medicine, Therapy

Our country is experiencing a childhood mental health crisis of epic proportions, with children waiting several months to receive a diagnosis and even longer to get into care.

Key Points: 
  • Our country is experiencing a childhood mental health crisis of epic proportions, with children waiting several months to receive a diagnosis and even longer to get into care.
  • When it comes to our childrens mental health, every second counts making todays average wait time even more unacceptable, said Yury Yakubchyk, co-founder and Chief Executive Officer, Elemy.
  • Today, providers offer therapy or medication management for a handful of childhood mental health issues, whereas Elemy provides integrated support for more than 15 pediatric behavioral health conditions.
  • The company's focus on virtual care provides access to people in rural areas far from city-based mental health specialists.

Nationwide Children’s Mental Health Survey Finds Disturbing Increase in Suicidal Thoughts and Self-Harm Throughout COVID-19 Pandemic

Retrieved on: 
Thursday, May 26, 2022
Family, Mental Health, Health, Consumer, Parenting, Children, General Health, Income, Social anxiety, Lists of diseases, Obsessive–compulsive disorder, Self-harm, SoftBank Group, Parent, Anxiety, Suicidal ideation, Bipolar disorder, COVID-19, General Catalyst, Sleep, Panic disorder, Attention deficit hyperactivity disorder, Awareness, Child, OCD, PTSD, ADHD, Oppositional defiant disorder, Founders Fund, Post-traumatic stress disorder, Behavior, CDC, Mental health, Suicide, ODD, Pharmaceutical industry, Residential care, Tutoring, Psychology

A national survey of parents conducted by Elemy ( https://www.elemy.com/ ) the nationwide provider of childhood behavioral and mental healthcare, revealed deeply concerning impacts the COVID-19 pandemic has had on childhood mental health.

Key Points: 
  • A national survey of parents conducted by Elemy ( https://www.elemy.com/ ) the nationwide provider of childhood behavioral and mental healthcare, revealed deeply concerning impacts the COVID-19 pandemic has had on childhood mental health.
  • Most importantly, results showed that suicidal ideation, self-harm and anxiety are very prominent in post-pandemic children today.
  • The survey of 1,028 parents of children under age 18 conducted in April 2022 is the first survey that takes a comprehensive look at how the pandemic continues to affect childrens mental health.
  • We have a clear childhood mental health crisis happening in the U.S. right now.

Gabrielle Pesaturo, PMHNP-BC Joins South County Psychiatry's Massachusetts Practice

Retrieved on: 
Tuesday, May 24, 2022
Dementia, Obsessive–compulsive disorder, Anxiety, Lists of diseases, CBT, Dialectical behavior therapy, Rhode Island Hospital, Psychiatric-mental health nurse practitioner, Patient, Tic disorder, University, Profile, MCPHS University, Premenstrual dysphoric disorder, Adult, Bipolar disorder, Depression, Telehealth, Psychotherapy, Bachelor of Science in Nursing, PTSD, OCD, ADHD, Bradley Hospital, Autism, United States Public Health Service, Post-traumatic stress disorder, NORTH, Mental health, Outline of health sciences, Attention deficit hyperactivity disorder, Nursing, PMDD, Medicine, Meat, MD, Science, Pharmacy

NORTH KINGTOWN, R.I., May 24, 2022 /PRNewswire-PRWeb/ -- Gabrielle Pesaturo, a Board-Certified Psychiatric Mental Health Nurse Practitioner, has joined South County Psychiatry, which recently expanded its practice area to serve patients in Massachusetts.

Key Points: 
  • Gabrielle Pesaturo, a Board-Certified Psychiatric Mental Health Nurse Practitioner, has joined South County Psychiatry, which recently expanded its practice area to serve patients in Massachusetts.
  • NORTH KINGTOWN, R.I., May 24, 2022 /PRNewswire-PRWeb/ -- Gabrielle Pesaturo, a Board-Certified Psychiatric Mental Health Nurse Practitioner, has joined South County Psychiatry , which recently expanded its practice area to serve patients in Massachusetts.
  • "We couldn't be prouder to welcome Gabrielle to our team," said Dr. Anthony Gallo, psychiatrist, and founder of South County Psychiatry.
  • We are thrilled that she has chosen South County Psychiatry as the practice that best matches her aims as a mental health care practitioner."

Neuronetics TMS Leadership on Display at Clinical TMS Society Annual Meeting

Retrieved on: 
Wednesday, May 11, 2022
Advanced Therapy Medicinal Product, Neuroscience, Radiology, NASDAQ, GLOBE, Obsessive–compulsive disorder, TMS, Columbia University, Clinical, Depression, Data collection, Patient, FDA, STIM, Industry, Anxiety, Transcranial magnetic stimulation, Adult, Quality of life, Marketing, Lists of diseases, MDD, Mental health, OCD, CEO, Research, Annual general meeting, Pharmaceutical industry, Medicine, Neuronetics, Psychiatry

Neuronetics will be the only Platinum Sponsor of the conference and will present new clinical updates from the NeuroStar Outcomes Registry.

Key Points: 
  • Neuronetics will be the only Platinum Sponsor of the conference and will present new clinical updates from the NeuroStar Outcomes Registry.
  • We are excited to attend and participate in the Clinical TMS Society Annual Meeting, leading the conversation in transcranial magnetic stimulation (TMS) treatment for depression, said Keith J. Sullivan, President and CEO of Neuronetics.
  • Neuronetics is the forerunner in data collection about real-world practices and outcomes with TMS.
  • NeuroStar is widely researched and backed by the largest clinical data set of any TMS system for depression, including the worlds largest depression Outcomes Registry.

NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Obsessive-Compulsive Disorder

Retrieved on: 
Tuesday, May 10, 2022
Advanced Therapy Medicinal Product, Neuroscience, NASDAQ, Disability, Lists of diseases, GLOBE, Obsessive–compulsive disorder, TMS, Major depressive disorder, Food, Obsessions, Depression, Patient, FDA, STIM, Industry, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Transcranial magnetic stimulation, Adult, Quality of life, Marketing, Compulsions, MDD, OCD, Mental health, VP, Pharmaceutical industry, Neuronetics, MD

This new indication means that NeuroStar can help even more people suffering from mental health disorders that can be debilitating in their daily lives.

Key Points: 
  • This new indication means that NeuroStar can help even more people suffering from mental health disorders that can be debilitating in their daily lives.
  • NeuroStar pioneered the TMS category as the first system FDA cleared for Major Depressive Disorder (MDD).
  • For more information about NeuroStar Advanced Therapy for Mental Health, please visit neurostar.com
    OCD is a mental health disorder characterized by uncontrollable thoughts and fears (obsessions), which may lead to repetitive behavior (compulsions).
  • The NeuroStar Advanced Therapy system is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).

Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA

Retrieved on: 
Wednesday, April 20, 2022
Research, FDA, Clinical Trials, Stem Cells, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Treatment, Manuscript, Society, Adult, U.S. Securities and Exchange Commission, COVID-19, Omeros, American Society of Clinical Oncology, News, Corporation, IgA nephropathy, Immune system, Journal of Clinical Oncology, SEC, Journal, Safety, Immunoglobulin A, Obsessive–compulsive disorder, Atypical hemolytic uremic syndrome, JCO, FDA, PNH, Cancer, Therapy, Pharmaceutical industry

The manuscript Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell TransplantationAssociated Thrombotic Microangiopathy will be published in an upcoming volume of the Journal of Clinical Oncology (JCO) and yesterday was made available online by JCO, the flagship publication of the American Society of Clinical Oncology.

Key Points: 
  • The manuscript Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell TransplantationAssociated Thrombotic Microangiopathy will be published in an upcoming volume of the Journal of Clinical Oncology (JCO) and yesterday was made available online by JCO, the flagship publication of the American Society of Clinical Oncology.
  • Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19.
  • OMS906, Omeros inhibitor of MASP-3, the key activator of the alternative pathway of complement, is initiating a Phase 1b clinical program in paroxysmal nocturnal hemoglobinuria (PNH).
  • In addition to its complement franchise, Omeros has ongoing cutting-edge programs in addiction treatments, immuno-oncology therapeutics and human CAR-T and adoptive T cell therapy systems.

Global Obsessive-Compulsive Disorder (OCD) Clinical Trials Market Review Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 31, 2022
Managed Care, Health, Clinical Trials, Obsessive–compulsive disorder, G7, E7, E7 (countries), Disorder, Central nervous system, Trial, Database, Clinical trial, Decision-making, Pharmaceutical industry

The "Obsessive-Compulsive Disorder - Global Clinical Trials Review, 2022" clinical trials have been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Obsessive-Compulsive Disorder - Global Clinical Trials Review, 2022" clinical trials have been added to ResearchAndMarkets.com's offering.
  • The report provides an overview of Obsessive-Compulsive Disorder Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Obsessive-Compulsive Disorder.
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Clinical Trials by G7 Countries: Proportion of Obsessive-Compulsive Disorder to Central Nervous System Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Obsessive-Compulsive Disorder to Central Nervous System Clinical Trials